Radiopharmaceutical provider DraxImage has received approval from the Canadian Health Protection Branch and Canadian Nuclear Regulatory Commission to manufacture and market its BrachySeed Pd-103 brachytherapy implant in Canada.
BrachySeed Pd-103 is indicated for the treatment of prostate cancer and other selected cancers, such as localized tumors of the head, neck, lung, pancreas, breast, and uterus, according to DraxImage. The Mississauga, Ontario-based firm expects to make BrachySeed Pd-103 commercially available in the U.S. later this year following approval by the U.S. Nuclear Regulatory Commission.
By AuntMinnie.com staff writersJuly 31, 2001
Related Reading
DraxImage gets clearance for palladium version of BrachySeed, June 28, 2001
DraxImage gets new president, June 20, 2001
DraxImage files for approval for brachytherapy implant, April 27, 2001
DraxImage licenses Infecton Agent, March 15, 2001
Copyright © 2001 AuntMinnie.com
